Accelerated Titration Designs for Phase I Clinical Trials in Oncology
Richard M. Simon,Boris Freidlin,Larry Rubinstein,Susan G. Arbuck,Jerry M. Collins,Michaele C. Christian +5 more
TLDR
Accelerated titration (i.e., rapid intrapatient drug dose escalation) designs appear to effectively reduce the number of patients who are under-treated, speed the completion of phase I trials, and provide a substantial increase in the information obtained.Abstract:
Background: Many cancer patients in phase I clinical trials are treated at doses of chemotherapeutic agents that are below the biologically active level, thus reducing their chances for therapeutic benefit. Current phase I trials often take a long time to complete and provide little information about interpatient variability or cumulative toxicity. Purpose: Our objective was to develop alternative designs for phase I trials so that fewer patients are treated at subtherapeutic dose levels, trials are of reduced duration, and important information (i.e., cumulative toxicity and maximum tolerated dose) needed to plan phase II trials is obtained. Methods: We fit a stochastic model to data from 20 phase I trials involving the study of nine different drugs. We then simulated new data from the model with the parameters estimated from the actual trials and evaluated the performance of alternative phase I designs on this simulated data. Four designs were evaluated. Design 1 was a conventional design (similar to the commonly used modified Fibonacci method) using cohorts of three to six patients, with 40% dose-step increments and no intrapatient dose escalation. Designs 2 through 4 included only one patient per cohort until one patient experienced dose-limiting toxic effects or two patients experienced grade 2 toxic effects (during their first course of treatment for designs 2 and 3 or during any course of treatment for design 4). Designs 3 and 4 used 100% dose steps during this initial accelerated phase. After the initial accelerated phase, designs 2 through 4 resorted to standard cohorts of three to six patients, with 40% dose-step increments. Designs 2 through 4 used intrapatient dose escalation if the worst toxicity is grade 0-1 in the previous course for that patient. Results: Only three of the actual trials demonstrated cumulative toxic effects of the chemotherapeutic agents in patients. The average number of patients required for a phase I trial was reduced from 39.9 for design 1 to 24.4, 20.7, and 21.2 for designs 2, 3, and 4, respectively. The average number of patients who would be expected to have grade 0-1 toxicity as their worst toxicity over three cycles of treatment is 23.3 for design 1, but only 7.9, 3.9, and 4.8 for designs 2, 3, and 4, respectively. The average number of patients with grade 3 toxicity as their worst toxicity increases from 5.5 for design 1 to 6.2, 6.8, and 6.2 for designs 2, 3, and 4, respectively. The average number of patients with grade 4 toxicity as their worst toxicity increases from 1.9 for design 1 to 3.0, 4.3, and 3.2 for designs 2, 3, and 4, respectively. Conclusion: Accelerated titration (i.e., rapid intrapatient drug dose escalation) designs appear to effectively reduce the number of patients who are undertreated, speed the completion of phase I trials, and provide a substantial increase in the information obtained. [J Natl Cancer Inst 1997;89:1138-47]read more
Citations
More filters
Journal ArticleDOI
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Peter C.C. Fong,D. S. Boss,Timothy A. Yap,Andrew Tutt,Peijun Wu,Marja Mergui-Roelvink,Peter S. Mortimer,Helen Swaisland,Alan Lau,Mark J. O'Connor,Alan Ashworth,James Carmichael,Stan B. Kaye,Jan H.M. Schellens,Jan H.M. Schellens,Johann S. de Bono +15 more
TL;DR: Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCa2 mutation.
Journal ArticleDOI
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.
Claudio G. Brunstein,Jeffrey S. Miller,Qing Cao,David H. McKenna,Keli L. Hippen,Julie M. Curtsinger,Todd E. DeFor,Bruce L. Levine,Carl H. June,Pablo Rubinstein,Philip B. McGlave,Bruce R. Blazar,John E. Wagner +12 more
TL;DR: There was a reduced incidence of grade II-IV aGVHD with no deleterious effect on risks of infection, relapse, or early mortality and the results set the stage for a definitive study of UCB Treg to determine its potency in preventing allogeneic aGV HD.
Journal ArticleDOI
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
Gerald S. Falchook,Georgina V. Long,Georgina V. Long,Razelle Kurzrock,Kevin B. Kim,Tobias Arkenau,Michael P. Brown,Omid Hamid,Jeffrey R. Infante,Michael Millward,Michael Millward,Anna C. Pavlick,Steven J. O'Day,Samuel C. Blackman,C. Martin Curtis,Peter F. Lebowitz,Bo Ma,Daniele Ouellet,Richard F. Kefford,Richard F. Kefford +19 more
TL;DR: Efficacy at the recommended phase 2 dose was studied in patients with BRAF-mutant tumours, including those with non-Val600Glu mutations, in three cohorts: metastatic melanoma, melanoma with untreated brain metastases, and non-melanoma solid tumours.
Journal ArticleDOI
Dose Escalation Methods in Phase I Cancer Clinical Trials
TL;DR: Dose escalation methods for phase I trials are reviewed, including the rule-based and model-based dose escalation methods that have been developed to evaluate new anticancer agents and specific methods for drug combinations as well as methods that use a time-to-event endpoint or both toxicity and efficacy as endpoints.
Journal ArticleDOI
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin.
Yasuhiro Matsumura,Tetsuya Hamaguchi,Takashi Ura,Kei Muro,Yasuhide Yamada,Yasuhiro Shimada,Kuniaki Shirao,Takuji Okusaka,Hideki Ueno,Masataka Ikeda,N Watanabe +10 more
TL;DR: The maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of NK911 were defined and a partial response was obtained in one patient with metastatic pancreatic cancer and its pharmacokinetic profile in man was well tolerated.
References
More filters
Book
The pharmacological basis of therapeutics
TL;DR: In this article, 42 authors share the herculean task of reviewing the flood of recent literature on pharmacology and rational use of drugs, under single or dual authorship they contribute the 76 chapters in the 18 sections.
Journal ArticleDOI
Continual reassessment method: a practical design for phase 1 clinical trials in cancer.
TL;DR: A new approach to the design and analysis of Phase 1 clinical trials in cancer and a particularly simple model is looked at that enables the use of models whose only requirements are that locally they reasonably well approximate the true probability of toxic response.
Journal ArticleDOI
Design and analysis of phase I clinical trials.
TL;DR: In Monte Carlo simulations, two two-stage designs are found to provide reduced bias in maximum likelihood estimation of the MTD in less than ideal dose-response settings and several designs to be nearly as conservative as the standard design in terms of the proportion of patients entered at higher dose levels.
Journal ArticleDOI
Some practical improvements in the continual reassessment method for phase I studies
TL;DR: Modifications to the Continual Reassessment Method (CRM) are presented, in which one assigns more than one subject at a time to each dose level, and each dose increase is limited to one level, which makes the CRM acceptable to clinical investigators.